Prexasertib is a potent and selective Chk1/Chk2 inhibitor. Prexasertib increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia. LY2606368 causes replication catastrophe and antitumor effects through CHK1-d

Prexasertib Mesylate Hydrate (LY2606368 Mesylate Hydrate) is an ATP-competitive, selective, second generation cell cycle detection site kinase 1 (CHK1) inhibitor (IC50<1 nM, Ki: 0.9 nM). Prexasertib Mesylate Hydrate inhibits CHK2 (IC50: 8 nM) and RSK1 (IC50: 9 nM). prexasertib Mesylate Hydrate causes double-stranded DNA breaks and replication mutations, induces apoptosis and exhibits potent anti-tumour effects.

IHCH-3064 is a tumour immunotherapeutic agent that targets both the adenosine A2A receptor and HDAC. IHCH-3064 effectively binds A2AR (Ki: 2.2 nM) and selectively inhibits HDAC1 (IC50: 80.2 nM). Prexasertib Mesylate